The ACER1 Knockout KYSE-150 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the KYSE-150 human esophageal squamous cell carcinoma line, in which the ACER1 gene has been disrupted to ablate alkaline ceramidase function. This loss-of-function model is provided as a mixed population, reflecting the polyclonal editing outcome, and serves as a versatile tool for studying sphingolipid-mediated signaling in cancer.
The parental KYSE-150 cell line originates from a poorly differentiated esophageal squamous cell carcinoma isolated from a Japanese male. These adherent cells are widely employed as a model of esophageal squamous cell carcinoma, retaining key oncogenic features and responsiveness to sphingolipid modulation. Their genetic background and tumorigenic properties make them a relevant system for functional genomics studies in esophageal cancer.
ACER1 encodes an alkaline ceramidase that catalyzes the hydrolysis of ceramides to generate sphingosine and free fatty acid, a critical step in sphingolipid catabolism. This enzyme is regulated by upstream factors including p53, retinoic acid, and differentiation stimuli, and its activity directly influences levels of downstream effectors such as sphingosine, sphingosine-1-phosphate (S1P), and ceramide. ACER1 interacts physically with ceramide substrates, sphingomyelinases (SMases), and Bcl-2 family proteins. Within the sphingolipid network, ACER1 functions in concert with ceramide synthases (CerS1-6), SMases, sphingosine kinases (SPHK1/2), S1P receptors (S1PR1-5), and S1P lyase. Disruption of ACER1 by CRISPR/Cas9 leads to accumulation of ceramide and depletion of sphingosine and S1P, thereby upsetting the sphingolipid rheostat that governs cell fate decisions.
In the context of KYSE-150 esophageal carcinoma cells, ACER1 knockout is expected to shift the ceramide/S1P balance toward ceramide-dominated signaling. This alteration can enhance ceramide-mediated apoptosis, potentially through mitochondrial pathways involving Bcl-2 family proteins, and may simultaneously attenuate pro-survival and migratory signals transduced by S1P receptors. Consequently, this polyclonal knockout population offers a physiologically relevant platform to dissect how sphingolipid metabolic flux influences esophageal cancer cell proliferation, apoptosis, and senescence.
Researchers can employ these polyclonal knockout cells to investigate ceramide-induced apoptosis mechanisms, elucidate the role of sphingolipid metabolism in esophageal tumor progression, evaluate ACER1 as a potential therapeutic target, and probe mechanisms of drug resistance. Representative experimental approaches include western blotting to confirm ACER1 ablation, LC-MS/MS-based ceramide quantification, ELISA for sphingosine/S1P, Annexin V apoptosis assays, MTT proliferation assays, transwell migration assays, and transcriptomic profiling via RNA-seq. These applications make the product suitable for studies in cancer biology, signal transduction, and drug discovery. For ordering or further information, please contact Ascent Research.
